CTOs on the Move

Zymergen

www.zymergen.com

 
Founded in 2013 and based in the San Francisco Bay Area, Zymergen integrates automation, machine learning, and genomics to rapidly accelerate the pace of scientific advancement. We treat the genome as a search space, leveraging machine learning to make discoveries far beyond the bounds of human intuition. In doing so, we deliver economic value, material diversity and performance capabilities not previously possible.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.zymergen.com
  • 5980 Horton Street Suite 105
    Emeryville, CA USA 94608
  • Phone: 415.801.8073

Executives

Name Title Contact Details
Dmitriy Ryaboy
Chief Technology Officer Profile

Funding

Zymergen raised $44M on 06/16/2015
Zymergen raised $130M on 10/11/2016
Zymergen raised $400M on 12/13/2018
Zymergen raised $300M on 09/08/2020

Similar Companies

Xigo Nanotools

Xigo Nanotools is a Morganville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

R mosaic health

R mosaic health is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Promeddx

Promeddx is a Norton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Trait Biosciences

Trait Biosciences Inc. is a leading biotechnology research organization providing proprietary technology to enable safer, lower cost, predictable, and superior quality cannabinoid products. With a world-class team of scientists and PhDs from more than 20 countries collaborating in our state-of-the-art Los Alamos laboratory, Trait Biosciences researchers are unlocking new breakthroughs in cannabinoid science. Trait Biosciences offers transformative technologies that create water-soluble cannabinoids, increase cannabinoid production, protect the plants from disease, tailor the production of cannabinoids and that can assure zero THC for hemp.

Vascular Biogenics Limited Therapeutics

VBL Therapeutics (NASDAQ: VBLT) is Phase 3 clinical biotechnology company using the machinery of the body to precisely address disease progression. The company has utilized its proprietary gene targeting and antibody platforms to create a pipeline of exquisite solutions for people with difficult to treat cancers and chronic inflammatory diseases. Our lead oncology candidate is Ofravec (VB-111), a first-in-class, targeted anti-cancer gene-therapy agent with a dual mechanism in development to target solid tumors. Ofravec is currently being studied in the OVAL international Phase 3 registration-enabling clinical trial to treat people with platinum-resistant ovarian cancer. Founded in 2000, VBL is based in Modiin, Israel and has recently opened operations in New York.